Add to Watchlist
View Current for ALXO
View SuperFeed for ALXO
View Charts for ALXO
Add or remove $ALXO from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
You have not created a stock watchlist. Create one now to track $ALXO!
Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its l… more
Explore popular threads around $ALXO
There are no threads for this stock
Go to Thread Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company ProfileALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc., as well as collaboration agreement with Sanofi to evaluate Evorpacept in combination with SARCLISA. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Market Cap Type: Small